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Background: The absence of a robust risk stratification tool for triple negative breast cancer 
(TNBC) underlies imprecise and non-selective treatment of these patients with cytotoxic 
chemotherapy. This study aimed to interrogate transcriptomes of TNBC resected samples using 
next generation sequencing (NGS) to identify novel biomarkers associated with disease 
outcomes. 
Methods: A subset of cases (n=112) from a large, diverse and well-characterised cohort of 
primary TNBCs (n=333) were subjected to RNA-sequencing (60M total reads/sample) and 
analyzed using the Illumina HiSeq 2500 platform. We identified genes associated with distant 
metastasis-free survival (DMFS) and breast cancer-specific survival (BCSS) by combining the 
application of supervised artificial neuronal network (ANN) analysis with gene selection to the 
RNA-sequencing data. The prognostic ability of these genes was validated using the Breast 
Cancer Gene-Expression Miner v4. 0 and Genotype 2 outcome datasets. Multivariate Cox 
regression analysis identified a prognostic gene signature that was independently associated 
with poor prognosis. Finally, we corroborated our results from the two-gene prognostic 
signature by their protein expression using immunohistochemistry. 
Results: ANN identified two gene panels that strongly predicted DMFS and BCSS. Univariate 
Cox regression analysis of 21 genes common to both panels revealed that the expression level 
of eight genes was independently associated with poor prognosis (p<0.05). Adjusting for 
clinicopathological factors including patient’s age, grade, nodal stage, tumor size, and 
lymphovascular invasion using multivariate Cox regression analysis yielded a two-gene 
prognostic signature (ACSM4 and SPDYC) which was associated with poor prognosis 
(p<0.05) independent of other prognostic variables. We validated the protein expression of 
these two genes, and it was significantly associated with patient outcome in both independent 
and combined manner (p<0.05). 
Conclusion: Our study identifies a prognostic gene signature that can predict prognosis in 





Breast cancer (BC) is a heterogeneous disease with variations in morphological features, 
molecular profiles, and therapy responses 1. Triple negative breast cancer (TNBC), defined by 
the absence of expression of Estrogen Receptor (ER), Progesterone Receptor (PR) and 
Human Epidermal Growth Factor 2 (HER2), comprises 15%-30% of BC, and presents 
considerable challenges with regard to clinical management due to lack of targeted therapies 
2,3. Moreover, TNBC often has an unfavourable prognosis with increased probability of early 
metastasis, disease recurrence, and shorter overall survival 4,5. Although TNBC generally 
displays aggressive behavior, patient outcomes can vary considerably. Around 23% of early-
diagnosed TNBC patients remain disease free for more than five years  while death within five 
years of diagnosis is inevitable for almost all metastatic TNBC patients 6–8. Therefore, the 
complexity, molecular variability, and unpredictability of TNBC behavior warrants further 
investigation 9. The biological heterogeneity of TNBCs has provided an impetus to develop 
tools for prognostic stratification, however, there are inconsistent results owing to a small 
cohort of patients, gene expression datasets obtained from different gene expression platforms 
and the use of microarray versus quantitative reverse transcriptase polymerase chain reaction 
(RT-PCR), which also makes head-to-head comparison challenging 10,11.  
Various multigene prognostic tests are available for ER-positive tumors for patient risk 
stratification and to guide therapy choice, whereas in ER-negative tumors, and specifically 
TNBC tumors with a higher proliferation rate, these multigene signatures provide no clinical 
value 12. Lehmann et al, used gene expression profiles to classify TNBCs into six molecular 
subtypes: Basal-like 1 and 2, Mesenchymal, Mesenchymal Stem-like, Immunomodulatory, 
and Luminal Androgen Receptor 13. Burstein et al proposed an alternative gene expression 
classification for TNBC  categorizing the tumor into four TNBC molecular subtypes: 
Luminal Androgen Receptor, Mesenchymal, Basal like immune suppressed, and Basal like 
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immune activated 14. However, distant metastasis-free survival (DMFS) analysis showed 
poor prognosis for TNBCs regardless of their molecular profile subtype 15. Therefore, there is 
an urgent unmet need for clinically validated prognostic markers that can predict outcomes 
for TNBC patients 15.  
Unbiased omics technologies, including Next Generation Sequencing (NGS), are expected to 
lead a paradigm shift for precision medicine from a pathological microscopy-based diagnosis 
to gene signature-based diagnosis, prognosis, and treatment approaches 16. NGS enables 
transcriptomic profiling of TNBC and identification of genomic alterations such as copy 
number changes, insertions, deletions and mutations; consequently, studies exploring inter-
tumor heterogeneity in different types of tumors are now possible 17,18. 
For successful NGS analysis, clinical samples must be maintained in conditions that would 
allow for DNA and RNA preservation and subsequent extraction. At present, most clinical 
samples are processed and archived as formalin-fixed, paraffin-embedded (FFPE) tissue 
samples in which the DNA and RNA necessary for NGS analysis is often fragmented 19. 
However, FFPE samples, if processed and stored properly, have been shown to preserve 
sufficient DNA and RNA material for extraction for NGS analysis 20. The present study utilizes 
NGS transcriptomic analysis of a large cohort of TNBC FFPE samples and aims to identify a 












Nottingham TNBC Cohort 
A retrospective well-characterised series of primary invasive TNBC (n=333) samples obtained 
from patients presented to Nottingham City Hospital, UK between 1987 to 2006, was included 
in this study. Clinicopathological data, including patient age at diagnosis, tumor size, tumor 
grade, nodal stage, lymphovascular invasion (LVI), and Nottingham Prognostic Index (NPI) 
were collected from patients’ medical records. The mean patient age was 48 years (range 27-
69) and tumor sizes in diameter at the time of presentation ranged from 0.25 – 8.00 cm (1.5-
2.8 cm within the interquartile), with a mean tumor size of 2.2 cm. Patients received a 
combination of treatment options including: surgery, radiation and chemotherapy according to 
standard protocols 21. Outcome data including BC-specific survival (BCSS) and DMFS were 
available and prospectively maintained. BCSS was defined as the time (in months) from the 
primary surgical treatment to the time of death from BC, while DMFS was defined as the 
duration (in months) from the time of primary surgery to the first occurrence of distant 
metastasis. ER, PR, and HER2 status of primary tumors were determined at the time of primary 
diagnosis from full-face sections of resected tumors according to published guidelines 22. (See 
Supplementary (A) for full details) 
Transcriptomic Analysis  
RNA sequencing was performed on representative FFPE tissue of an in house TNBC cohort 
(n=112) which had also been assessed histopathologically for tumor burden. (See 
Supplementary (A) for full details). Artificial Neural Network (ANN) database mining 
approach was used to build a classifier using the RNA-sequence matrices and identify genes 
associated with disease outcomes (DMFS and BCSS). In ANN, learning rates and momentum 
6 
 
were set at 0.1 and 0.5, respectively 23. Each tumor sample had 39,684 corresponding genes. 
The input codes were “0” if patients showed neither evidence of metastasis (DMFS) nor death 
from BC (BCSS) within five years, and “1” if metastasis or death due to BC was evident in the 
first five years after diagnosis. Although BCSS is the ultimate endpoint of cancer outcome, 
DMFS was chosen as an end point based on the high likelihood of TNBC patients being 
diagnosed with distant metastases within five years of diagnosis 8. Prior to ANN testing, a 
Monte-Carlo cross validation procedure was applied to avoid data over-fitting and false 
discovery. Documentation of such approach has proven to outperform the commonly used 
leave-one-out cross validation 24. The input data were randomly divided into three subsets; 60% 
for training, 20% for validation to ensure model performance during the training process, and 
20% for blind testing of the original model 25. Genes identification by the forward stepwise 
approach using ANN was performed as described previously 26. Based upon the distribution of 
performance on aforementioned model, ANN generated two panels of genes, representing the 
top 1% of the RNA sequence matrices that significantly predicted DMFS and BCSS, 
respectively. Genes common to both the DMFS and BCSS panels were identified using the 
Venny 2.0 online tool 27. Receiver operating characteristics (ROC) curves were generated to 
assess the predictive value of the differentially expressed gene panel presenting the sensitivity 
and specificity of the tested model (Supplementary (B) Figure 1). 
Pathway Analysis  
The online publicly available web-based gene set analysis tool, Webgestalt, 
(http://www.webgestalt.org/option.php) was used to identify differentially regulated canonical 
pathways using the overrepresentation enrichment analysis (ORA). The pathway analysis was 
based on the top 200 ranked genes predicting DMFS and BCSS. The reference gene list was 
set to the “genome_protein_coding”. The ratio of observed versus expected number of genes 
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in the category was recorded for each significant category using the enrichment ratio (R) scores 
using Panther pathway database 28. 
Prognostic Gene Signature Score 
In compliance with the Reporting Recommendations for Tumor Marker Prognostic Studies 
criteria (REMARK), the associations between the expression of genes in our 21-gene panel, 
common to both the DMFS and BCSS  gene prediction panels identified by ANN, and  DMFS 
or BCSS were evaluated both individually, as well as after adjusting for standard prognostic 
variables 29,30. Thus, DMFS and BCSS probabilities were individually computed on our gene 
panel using Kaplan-Meier testing model. Additionally, multivariate Cox regression analysis 
was used to calculate the estimate effect size [i.e., Hazard ratio (HR), along with 95% 
confidence interval (CI)] of the genes that were statistically significant in univariate Kaplan-
Meier testing model for both DMFS and BCSS, which included the genes and standard 
prognostic variables, regardless of the statistical significance of standard prognostic variables 
in univariate analysis. The genes which showed significant prognostic impact independently in 
multivariate Cox regression analysis were further examined in a combined multivariate Cox 
regression analysis to identify a signature with a minimum number of genes that showed the 
most significant association with DMFS and BCSS. 
External Validation of Transcriptomic Data 
For independent validation of the results, the prognostic value of the two-gene signature 
predictors of DMFS and BCSS were evaluated using the Breast Cancer Gene-Expression 
Miner v4. 0 (Bc-GenExMiner) database which includes RNA-sequence expression data from 
4713 BC patients, including 254 TNBC patients 31. These genes were also interrogated 
through the Genotype 2 outcome tool (http://www.g-2-o.com), a web-based server utilizing 
NGS and gene chip data of 6,697 breast cancer patients including 612 TNBC patients with 
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outcome data. Computed ROC values were used to generate the transcriptomic fingerprint for 
mutational status from The Cancer Genome Atlas RNA-sequence and NGS mutation data. The 
average expression of significant genes was designated as a metagene for a given genotype. By 
employing gene chip data, associations between the expression of the metagene and patient 
outcomes were computed by multivariate Cox regression and Kaplan-Meier survival analysis 
32. 
 Immunohistochemistry  
Assessment of the protein expression of the identified two-gene prognostic signature was 
performed using rabbit anti-SPDYC (NBP1-80832, lot # R36476, Novous Biological, UK) and 
rabbit anti-ACSM4 (PA5-62082, lot # R59771, Thermofisher, UK) antibodies on tissue 
microarrays (TMAs) prepared for the IHC cohort. (See Supplementary (A) for full details) 
Statistical Analysis 
IBM SPSS 24.0 (Chicago, IL, USA) software was used for statistical analysis. For 
dichotomization of mRNA expression and protein expression levels of different genes, the X-
tile bioinformatics version 3.6.1 (Yale University, USA) was utilised with DMFS as an 
endpoint. Cox proportional hazard models were used for multivariate analysis model adjusting 
for patients age, tumor grade, nodal stage, tumor size, and LVI status as covariates to adjust for 
potential confounding influence of these variables on associations between the tested genes 
and the outcomes of interest. Spearman’s Rho test was used to evaluate correlations between 
continuous variables of the transcriptomic and protein expression data whereas the chi-
square test was performed to analyze relationships between categorical variables. A p-value of 






Gene Selection  
To build a classifier panel for outcome prediction in TNBC, ANN analysis of the RNA-
sequence matrices data of the transcriptomic cohort was performed and genes were ranked 
based on relationships between their expression and clinical outcomes in terms of DMFS and 
BCSS. The top ranked genes predicting DMFS (DMFS genes panel) and those predicting 
BCSS (BCSS genes panel) were investigated to determine the most statistically enriched 
pathways (Supplementary (A) Table 2 & Supplementary (C) for full details) 
Using the Venny tool, we identified a total of 21 genes that were common to both the DMFS 
and BCSS ANN panels. The 21-gene panel predicted patients’ DMFS and BCSS with 92% 
sensitivity and 94% specificity (Supplementary (B) Figure 2). The probability of finding a gene 
by random chance in the top 200 was 0.03, whereas the probability of randomly finding the 21 
genes collectively was 6.2x10-33 (Supplementary (B) Figure 3). 
Univariate Kaplan–Meier survival analysis showed that elevated expression of some genes was 
significantly associated with shorter DMFS and BCSS, whereas elevated expressions of other 
genes showed statistically significant association with longer DMFS and BCSS 
(Supplementary (A) Table 3 & Supplementary (B) Figures 4 A-D). Multivariate Cox regression 
analysis models incorporating patient’s age, tumor grade, nodal stage, tumor size, and LVI 
status revealed that eight of the 21 genes were independent predictors of DMFS and BCSS 
(Supplementary (A) Table 4 A-D). 
 
Prognostic Two-Gene Signature 
The prognostic gene signature was identified after statistically distilling the eight genes in a 
multivariate Cox regression analysis to identify a signature with a minimum number of genes 
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that show most significant association with BCSS and DMFS. The  analysis revealed two 
genes ACSM4 and SPDYC that most significantly and  independently predicted both DMFS 
and BCSS (ACSM4; DMFS: p=0.015, 95% CI=1.21-6.13, HR=2.72 : BCSS: p=0.004, 95% 
CI=1.44-6.83, HR=3.14), and (SPDYC ; DMFS: p=0.012, 95% CI=1.23-5.45, HR=2.59 
:BCSS: p=0.016, 95% CI=1.18-5.09, HR=2.45) (Supplementary (A) Table 5). In addition, a 
weak positive linear association between the mRNA expression of ACSM4 and SPDYC (r = 
0.036, p=0.710) was identified, suggesting that these genes might be collaboratively 
promoting disease progression. To investigate the prognostic value of the two-gene signature, 
a linear prognostic score was generated using the sum of the product of normalized 
expression levels of these two genes and their respective regression coefficients, as follows:  
The prognostic two-gene signature score ∑= (ACSM4 normalized expression * ACSM4 
expression β-value) + (SPDYC normalized expression * SPDYC expression β-value) 
(Table1). 
Using X-tile cut-off generator, patients with higher mRNA expression score of the prognostic 
two-gene signature had worse outcome in terms of shorter DMFS and BCSS when compared 
with those with lower mRNA expression score (Figure 1). Cox regression analysis confirmed 
that the prognostic two-gene signature harbours significant prognostic value in terms of 
predicting shorter DMFS and BCSS independent of patient age, tumor grade, nodal stage, 
tumor size, and LVI status (Table 2). 
External Validation of Genomic Findings 
Using the Bc-GenExMiner tool to analyze publicly available RNA-sequencing data, we 
observed that higher expression of SPDYC was significantly associated with worse prognosis 
in the whole/unselective cohorts of BC (n=4308, p<0.0001) 31. Validating genes expressions 
on the restricted TNBC cohort (n=254), revealed a similar trend of poor prognosis (p=0.006) 
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31. Moreover, the integration of our proposed prognostic two-gene signature in the public 
domain Genotype 2 outcome, using the median of each gene expression in  the 
whole/unselective cohorts of BC (n=4029), indicated that higher expression of ACSM4 and 
SPDYC were associated with worse prognosis (both p<0.001). More importantly in the context 
of this study, the prognostic value of the two-gene signature (ACSM4 and SPDYC) were 
significantly associated with poorer outcome when examined in the TNBC subtype cohort 
alone (n=612, p<0.001) 32 (Figure 2). 
Immunohistochemistry of the Prognostic Two-Gene Signature  
The morphological assessment of the tissue samples revealed cytoplasmic expression for both 
proteins; ACSM4 (H-score range 5-295) and SPDYC (H-score range 5-290) (Supplementary 
(B) Figure 5).  
Univariate survival analysis revealed that higher expression of ACSM4 and SPDYC was 
significantly associated with patients’ poor outcomes (DMFS; p<0.001, BCSS; p=0.009 for 
ACSM4) and (DMFS and BCSS, both p=0.004 for SPDYC) (Figure 3), which is concordant 
with the findings obtained from transcriptomic data.  
Multivariate Cox regression analysis showed that SPDYC protein expression was an 
independent prognostic factor regardless of patient age, tumor grade, nodal stage, tumor size, 
and LVI status for DMFS (p=0.015, 95% CI =1.17 - 4.74, HR=2.365) and BCSS (p=0.015, 
95% CI =1.18- 4.78, HR=2.377). Likewise, multivariate Cox regression analysis showed that 
ACSM4 protein expression was a significant independent prognostic factor for DMFS 
(p=0.002, 95% CI=1.35- 3.89, HR= 2.267), but not in BCSS (p=0.057, 95% CI=0.98- 2.93 , 
HR= 1.698) (Table 3 A & B). 
In a combined multivariate Cox regression analysis, SPDYC protein expression was an 
independent prognostic factor that predicted shorter  DMFS and BCSS ( DMFS: p=0.03, 95% 
CI=1.07-5.86, HR=2.50: BCSS: p=0.03, 95% CI=1.08-5.96 HR=2.54), regardless of patient 
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age, tumor grade, nodal stage, tumor size, and LVI status. ACSM4 protein expression also was 
observed to be an independent prognostic factor, associated with shorter DMFS (p=0.003, 95% 
CI =1.01-3.20, HR=1.83), regardless of patient age, tumor grade, nodal stage, tumor size, and 
LVI status, but not with BCSS (p=0.27, 95% CI=0.76-2.56 , HR=1.40) (Table 4). 
Correspondingly, we observed a significant positive linear association between ACSM4 and 
SPDYC protein expression (r=0.29, p<0.001), signifying that these proteins might be 
synergistically driving TNBC disease progression (Figure 4). Furthermore, using only cases 
that were informative for both biomarkers, a linear prognostic score was generated using Cox 
proportional hazard analysis to test whether dual expression of SPDYC and ACSM4 proteins 
was associated with worse outcome. The equation generated used the sum of the product of the 
quantitative H-score and their respective regression coefficient as follows:  
Protein expression prognostic score: ∑= (ACSM4 H-score * ACSM4 H-score β value) + 
(SPDYC H-score * SPDYC H-score β value) (Table 5).  
This protein expression prognostic score was then dichotomised using X-tile software to 
determine the optimal score to classify patients into high and low risk groups using DMFS as 
an end point. In the 257 investigated cases, the scores ranged from 15.43-365.05 with high 
protein expression risk scores (score > 170) observed in 159/257 (62%) cases. 
When testing the association between the prognostic score and outcome, univariate analysis 
demonstrated that cases with higher protein expression score had a significantly shorter DMFS 
(p=0.02) but not BCSS (p=0.06) (Figure 5). Multivariate Cox regression analysis model 
demonstrated that protein expression prognostic score was an independent prognostic factor 
for DMFS (p=0.03, 95% CI=1.04- 3.32 , HR=1.83) independent of patient age, tumor grade, 
nodal stage, tumor size, and LVI status, but not for BCSS (p=0.07, 95% CI=0.94-2.96, 
HR=1.83) (Table 6). 
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Finally, when we stratified our cohort based on chemotherapy treatment, the 10-year DMFS of 
patients who were not offered chemotherapy (n=83) and showed low expression of ACSM4 
was 84% compared to 44% of those with high expression and the difference was statistically 
significant (p=0.005). However, those with low expression of SPDYC had 83% 10-year DMFS 
compared to 70% in those with high expression but the difference was not statistically 
significant (p=0.209). Similarly, with the prognostic two gene signature, the 10-year DMFS of 
patients with low expression was 84% compared to 69% of those with high expression 
(p=0.309).  
Testing the performance of the prognostic two-gene at the transcriptomic and protein 
Levels:  
The prognostic signature at the mRNA level captured 58% sensitivity, 69% specificity, 54% 
positive predictive value (PPV), 72% negative predictive value (NPV), and 64% accuracy in 
dichotomising distant metastasis outcome of TNBC patients. In comparison, the prognostic 
signature at the protein level showed 73% sensitivity, 42% specificity, 30% PPV, 82% NPV, 
and 50% accuracy in dichotomising distant metastasis outcome of TNBC patients 




Molecular classification of BC provides opportunities for enhanced personalised therapy 33. In 
TNBC, conventional prognostic factors such as age, tumor size, tumor grade, and lymph node 
status have limited risk-predictive influence as these tumors are mostly of higher grade with 
increased chances of recurrence and metastasis 1. Therefore, deciphering genomic profiles of 
TNBC using advanced techniques is an unmet need. Moreover, the utilization of ANN to mine 
the transcriptomic profile of TNBC in order to identify genes associated with clinical outcome 
is a promising approach to stratify patients for risk prediction 34. 
In the current study, a discovery phase and two validation phases were implemented. The in-
house transcriptomic TNBC cohort was used for the discovery phase for ANN analysis. 
Whereas the protein expression and publicly available external transcriptomic BC data were 
used for the validation phases of findings. More importantly, regardless of the statistical 
differences in the distribution of clinicopathological parameters between transcriptomic and 
IHC cohorts, our gene signature showed statistical association with outcome both at 
transcriptomic and protein expression level. Our study supports the utility of applying ANN to 
integrate distinct clinical and molecular data to find novel prognostic biomarkers associated 
with TNBC poor outcome.  
Our study employed ANN for the analysis of our transcriptomic cohort to discover novel 
prognostic genes associated with outcome in TNBC. ANN is a powerful tool for the analysis 
of complex data, overcoming high background noise, and thus identifying the influence of 
many interacting factors 35. ANN analysis, unlike conventional statistical approaches such as 
hierarchical clustering, linear regression, and principal component analysis, is not limited by 
linear functionality; thus, identification of biological relationships between biomarkers and 
clinical outcomes is improved 24. Furthermore, unlike conventional statistical techniques used 
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in the medical diagnostic and prognostic approaches, ANN can produce greater accuracy model 
than its counterparts 36. Therefore, it is highly suitable for the identification of potential key 
genes driving TNBC outcomes. ANN modelling uses a supervised learning approach, a multi-
layer perception architecture with a sigmoid transfer function, where weights are updated by a 
back propagation algorithm 37. 
In this study, ANN analysis identified the top ranked genes predicting DMFS and BCSS. We 
then employed a web-based tool to identify the signalling pathways significantly enriched in 
the significant top ranked gene panels. For instance, TNBC patients frequently harbour higher 
expression of EGFR; however, studies have failed to establish significant benefit from EGFR-
targeted therapies or tyrosine kinase inhibitors, suggesting the need to therapeutically target 
other pathways in these tumors 38,39. Moreover, the significance and over-activation of 
pathways such as; P38 MAPK , the PDGF, and the RAS pathways in BC metastatic sites and 
their association with DMFS and BCSS in TNBC have been previously documented 40–42. 
Additionally, the 21 gene panel generated by ANN analysis that was strongly associated with 
both DMFS and BCSS in TNBC included several novel and potentially targetable biomarkers 
in TNBC outcome. For instance, higher expression of DOCK10 (also known as dedicator of 
cytokeratin-10/ZIZ3) 43, has been previously identified as an indicator of poor prognosis in 
TNBC patients and as a predictor of distant metastasis 44. In our transcriptomic cohort, 
DOCK10 emerged as a significant prognostic marker of BCSS and DMFS however, it was not 
significantly prognostic in multivariate Cox regression analysis. We also found that high 
expression of BICC1, an RNA binding protein, a negative regulator of  the WNT  signalling 
pathway with potential involvement in regulating gene expression during embryonic 
development 45, was associated with DMFS but not with BCSS; thus, it was not included in the 
final signature.  
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In our study, we distilled the initial 21 gene panel down to eight genes that when tested 
individually for their prognostic value, were significantly associated with both DMFS and 
BCSS using univariate and multivariate analysis after adjusting for the potentially confounding 
variables. These genes are implicated in pro-oncogenic pathways in BC. PPL is a part of the 
cornified envelop in keratinocytes and desmosomes with intermediate filaments. PPL can act 
in the PKB/AKT-mediated signalling pathway 46. In TNBC, silencing PPL decreased cell 
migration and invasion 47. SPDYC is a member of the speedy/Ringo cyclin-dependent kinase 
(CDK) family with known functions in cell cycle transitions and progression 48. SPDYC plays 
an important role in activating both CDK1 and CDK2 expression 49. CDK2 high expression  
has been previously described to be  associated with shorter survival in metastatic melanoma 
cases and endocrine resistance in SKBR3-HER2 positive BC cell lines 50,51. Furthermore, down 
regulation of CDK1 has been found to increase synthetic lethality of TNBC cell lines if 
accompanied with c-Myc over expression 52. However, SPDYC role in BC is still undefined 48. 
ACSM4 encodes a protein with known functions in the conjugation of carboxylic acids and in 
fatty acid beta oxidation. Interestingly, upregulation of metabolic pathways has been found to 
interact with cellular transcriptomic and proteomics of both CD4 and CD8 T cells in HIV 
disease 53. Although ACSM4 has been shown to have a role in AIDS progression, there are no 
reports with its role in BC 54,55. We have previously reported a strong correlation between tumor 
infiltrating lymphocytes (TILs) and TNBC outcome 56. However, our current analysis did not 
identify known inflammation and immune response related genes associated with outcome in 
the TNBC 21 gene panel. Future studies should therefore seek to identify novel mechanisms 
contributing to aberrant inflammatory and immune response pathways involved in TILs in 
TNBC. Furthermore, genes such as AC020931.1, DCTN1-AS1, RP11-29H23.5, PAXBP1-AS1, 




The original hypothesis underpinning this study was that a signature of genes would more 
accurately predict both DMFS and BCSS in TNBC than a single gene. Multivariate Cox 
regression analysis enabled us to further filter the set of eight genes to a prognostic two-gene 
signature (ACSM4 and SPDYC) showing strong association with both DMFS and BCSS. We 
tested whether immunohistochemical assessment of the protein expression of the ACSM4 and 
SPDYC genes could be used to predict patient outcomes. Our study confirmed that protein 
expression had independent prognostic significance in TNBCs and showed strong statistical 
association with worse outcomes (i.e., shorter DMFS and BCSS). These genes when combined 
in a linear score, successfully stratified TNBC patients into high- and low-risk subgroups; in 
the former group, which is at a higher risk of developing distant metastasis, could benefit from 
greater vigilance and more aggressive treatment regimens. We have validated our ANN 
investigation and RNA-sequencing results by studying protein expression which showed that 
a prognostic score derived from the immunohistochemical evaluation of the two biomarkers 
could significantly predict distant metastasis, and thus support personalized prognostic 
evaluation and guiding treatment choices to improve disease outcomes. 
In this study, the prognostic value of the two-gene signature at the mRNA level yielded 58% 
sensitivity, and 64% accuracy in dichotomizing distant metastasis outcome of TNBC patients. 
By contrast, at the protein level, our proposed two-gene signature demonstrated 73% 
sensitivity, and 50% accuracy in dichotomizing distant metastasis outcome of TNBC patients. 
Our proposed two-gene signature showed promising accuracy and sensitivity results in 
predicting the risk of distant metastasis in TNBC patients, which is even more important as 
presently TNBC patients solely rely on chemotherapy treatment. Moreover, those patients who 




Furthermore, our proposed two-gene signature is only based on two genes (ACSM4 and 
SPDYC), unlike other commercially available prognostic assays including those designed for 
ER-positive tumors 57. Our prognostic gene signature may be amenable to the development of 
affordable molecular tests based on quantitative RT-PCR as the sensitivity, specificity, and 
accuracy of our two-gene signature is proved to be much stronger at the mRNA level. The 
prognostic gene signature might be suitable for use in routine clinical practice because the 
proposed two-gene signature has prognostic value in dichotomizing TNBC patients and may 
provide important information for treatment decisions.  
The mainstay of TNBC treatment is cytotoxic chemotherapy 58. However,  chemotherapy 
decision for metastatic TNBC patients are given based on a combination of aspects relates to 
the disease and patient physical characteristics (i.e., tumor burden, patient age, co-morbidities, 
prior treatments received in the adjuvant setting, and patient preference) 59.  Despite the 
interesting finding of this study and the significant difference in the survival of patients who 
were not offered chemotherapy based on the expression of ACSM4 (with worse outcome of 
patients with over expression), the 10-year DMFS of patients with low expression (84%) may 
not justify recommendation for omission of chemotherapy in those patients. However, to make 
such a recommendation, a clinical trial utilizing a sufficiently large number of TNBC patients 
may be warranted to determine whether TNBC patients with low ACSM4 expression can avoid 
chemotherapy without worse outcome. 
A challenge  of the NGS technique in deciphering the molecular characteristics of TNBC 
tumors includes  access to the technology and the integrity of tumor samples to guarantee 
sufficient tumor RNA extraction 60. Variation in sample quality and preparation may negatively 
influence the outputs of NGS analysis and therefore must be carefully controlled. In addition, 
NGS analysis must consider intrinsic tumor heterogeneity between patients. Samples used in 
this study were processed in a strictly standardized procedure implemented in Nottingham 
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University Hospitals with immediate sample fixation following surgery, with standard 
protocols optimized to preserve tissue architecture, subcellular details and importantly the 
integrity of biologic materials including proteins, DNA, and RNA. Nonetheless, our 
retrospective study was limited to a single centre using an in-house transcriptomic and protein 
expression cohort for this investigation. However, the public domain data used in this study 
supports the value of both ACMS4 and SPDYC high expression conferring poor prognosis for 
BC patients, especially those diagnosed with TNBC molecular subtype. Hence, future external 
validation is strongly recommended.  
Conclusion 
Personalised medicine seeks to stratify BC patients ensuring optimal treatment and thus, 
improved patient outcomes. Our study has identified a two-gene signature that stratifies TNBC 
patients into high and low risk groups for developing distant metastasis, which can potentially 
guide clinical decision-making. The robust methods used herein to identify our prognostic gene 
signature followed by validation of the findings at the protein expression level, suggest that 
this promising two-gene signature  provides avenues for further in vitro functional investigation 











This research received no specific grant from any funding agency in the public, commercial, 
or not-for-profit sectors. The RNA sequencing was supported by grants to RA from the 
National Cancer Institute (R01 CA169127, U01 CA179671, and R03 CA188527). The IHC 
was supported by the PhD scholarship funded by the Saudi Arabia Ministry of Education 
Qassim University. 
Conflict of Interest 
The authors have no conflicts of interest to declare.  
Ethical Approval and Consent to Participate 
This work obtained ethics approval by the North West – Greater Manchester Central Research 
Ethics Committee under the title; Nottingham Health Science Biobank (NHSB), reference 
number 15/NW/0685. Informed consent was obtained from all individuals prior to surgery to 
use their tissue materials in research. All samples used in this study were pseudo-anonymized 
and collected prior to 2006 and stored in compliance with the UK Human Tissue Act.  
Availability of Data and Materials 
The authors confirm the data that has been used in this work is available on reasonable request. 
Authors’ Contributions 
MAA, MA, and GB participated in its conception, design, experimentation, analysis, 
interpretation, and manuscript drafting. MAA and MS conducted the immunohistochemical 
studies and participated in the analysis and interpretation. MS and MA helped with pathology 
review and manuscript drafting. SR, and CJ helped in immune-histochemical analysis and 
interpretation. AO, SB, PR, FK, MD, OE, RA, IE, AG and NM participated in interpretation 
and manuscript drafting. ER conceived and supervised the study, participated in its design, 
21 
 
interpretation, and analysis, including drafting. All authors contributed to drafting and 
reviewing the manuscript and approved the submitted and final version. 
Acknowledgements 
Mansour A Alsaleem is supported and funded by Qassim University, Kingdom of Saudi 
Arabia. We express thanks to Innovate UK for funding (ISCF bid Ref 18181), and the 






















Figure 1 legend: Univariate Kaplan Meier survival analyses to test associations between 
prognostic two gene signature at the transcriptomic level and clinical outcomes. 
(Transcriptomic Cohort, n=112) 
Figure 2 legend: To validate our findings, we utilised the Breast Cancer Gene-Expression 
Miner v4.0 (bc-GenExMiner v4.0) datasets which includes 5861 breast cancer patients & 
Genotype 2 outcome public portal, A genome-wide approach to link genotype to clinical 
outcome by utilising next generation sequencing and gene chip data of 6,697 breast cancer 
patients. A) In the Breast Cancer Gene-Expression Miner data portal, high SPDYC mRNA 
expression confers a poor prognosis in the whole (i.e. unselected cohorts) of Breast cancer 
patients (n=4308, p value<0.0001). B) In the Breast Cancer Gene-Expression Miner data 
portal, high SPDYC mRNA expression confers poor prognosis in the Triple Negative Breast 
Cancer patients (n=254, p value=0.006). C) In the Genotype 2 outcome public portal, high 
ACSM4 mRNA expression confers a poor prognosis outcome in the whole (i.e. unselected 
cohorts) of Breast cancer patients (n=4029, p value<0.0001). D) In the Genotype 2 outcome 
public portal, high SPDYC mRNA expression confers a poor prognosis outcome in the whole 
(i.e. unselected cohorts) of Breast cancer patients (n=4029, p value<0.0001). E)  In the 
Genotype 2 outcome public portal, high SPDYC& ACSM4 mRNA expression confers a poor 
prognosis outcome in Triple Negative Breast Cancer patients (n=612, p value<0.0001). 
Figure 3 legend: Univariate Kaplan Meier survival analyses to test associations between the 
ACSM4 and SPDYC protein expression and clinical outcomes (IHC Cohort, n=333) 
Figure 4: Violin plots demonstrating a positive correlation between protein expressions of SPDYC 
and ACSM4 (Correlation Coefficient, r=0.29, P=0.00001) (IHC Cohort, n=333). 
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Figure 5 legend: Univariate Kaplan Meier survival analyses to test associations between the 
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